Ernexa Therapeutics

Ernexa Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing engineered mRNA cell therapies for advanced cancer and autoimmune disease. The company's pipeline is built on a patented mRNA cell-engineering platform designed to program immune cells in vivo, with a focus on solid-tumor and immune-mediated indications. Ernexa trades on Nasdaq under the symbol ERNA and executed a 1-for-25 reverse stock split effective May 4, 2026 to address its minimum-bid-price listing compliance. In July 2026 the company furnished an updated investor presentation via Form 8-K, refreshing materials originally posted in February 2026 to provide current company information and forward-looking statements to investors.